Evidence map›Paper›PMID 32140533›Full record

ArticleGynecologic oncology reports2020

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma.

Silvia Pelligra, Natalia Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner, Peter E Schwartz, Giovanni Scambia, Alessandro D Santin

Erratum issuedOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Uterine serous carcinoma.Gynecologic oncology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Silvia PelligraDepartment of Obstetrics, Gynecology, and Reproductive Sciences, New Haven, CT 06520, USA.
Natalia BuzaDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
Pei HuiDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
Stefania BelloneDepartment of Obstetrics, Gynecology, and Reproductive Sciences, New Haven, CT 06520, USA.
Burak ZeybekDepartment of Obstetrics, Gynecology, and Reproductive Sciences, New Haven, CT 06520, USA.
Elena RatnerDepartment of Obstetrics, Gynecology, and Reproductive Sciences, New Haven, CT 06520, USA.
Peter E SchwartzDepartment of Obstetrics, Gynecology, and Reproductive Sciences, New Haven, CT 06520, USA.
Giovanni ScambiaDivision of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Alessandro D SantinDepartment of Obstetrics, Gynecology, and Reproductive Sciences, New Haven, CT 06520, USA.
Yale University · USAgostino Gemelli University Polyclinic · IT

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Integrated genomic analysis of racial disparities in endometrial cancerU01CA176067 · NCI · YALE UNIVERSITY · PI SANTIN, ALESSANDRO D · 2014 to 2018
$1.7M
NCATS NIH HHS UL1 TR001863NCI NIH HHS U01 CA176067
6 · The paper itself

Abstract

backgroundUterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, in combination with carboplatin/paclitaxel, is considered the preferred regimen for the treatment of advanced or recurrent HER2/Neu+ USC per NCCN guidelines. CASE: We describe two USC patients with overexpression of HER2/neu at 2+/3+ level by immunohistochemistry and c-erbB2 gene amplification by fluorescence in situ hybridization (FISH) assay that, after an initial clinical response to trastuzumab, developed resistance/progression. Post-treatment biopsy (collected at the time of clinical progression on trastuzumab) demonstrated loss of HER2/neu overexpression in the recurrent/progressing tumor cells in both patients.

conclusionSelection of HER2/NEU negative tumor cells may represent a major mechanism of resistance to trastuzumab in USC patients.

Indexed as

HER2/neuRecurrentTrastuzumabTreatment-resistantUterine serous carcinoma

Identifiers

PMID32140533
PMCPMC7049633
OpenAlexW3007117572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.